ROSLINCT
LIVE

Serial Number

97913008

Owner

Roslin Cell Therapies Limited

Attorney

Benjamin P. Harbuck

First Use Date

Aug 4, 2015

Filing Date

Apr 28, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ROSLINCT Trademark

Serial Number: 97913008 • Registration: 7771028

ROSLINCT is a trademark filed by Roslin Cell Therapies Limited on April 28, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Roslin Cell Therapies Limited (2 trademarks)

NINE Edinburgh BioQuarter
Edinburgh EH164UX , GB

Entity Type: 99

Trademark Details

Filing Date

April 28, 2023

Registration Date

April 22, 2025

First Use Anywhere

August 4, 2015

First Use in Commerce

May 6, 2023

Published for Opposition

May 14, 2024

Goods & Services

Education and training services, namely, classes, seminars, tutorials, conferences and workshops in the fields of cell therapy and gene therapy; provision of online education, training and teaching services, namely, classes, non-downloadable webinars and tutorials in the fields of cell therapy and gene therapy; arranging, organising and conducting of colloquiums, conferences, congresses, seminars and symposiums in the fields of cell therapy and gene therapy; publication of books, scientific papers and texts in the fields of cell therapy and gene therapy; information, advisory and consultancy services related to the aforesaid

Contract manufacturing of pharmaceutical and biopharmaceutical products in the fields of cell therapy and gene therapy; contract manufacturing in the fields of cell therapy and gene therapy; custom manufacturing of pharmaceutical and biopharmaceutical products in the fields of cell therapy and gene therapy; custom manufacturing in the fields of cell therapy and gene therapy; custom fabrication and production of cells for others; manufacturing process consulting in the fields of cell therapy and gene therapy; information, advisory and consultancy services related to the aforesaid

Business information, consultancy and management services in the fields of designing, building, testing and validating processes and systems for use in cell therapy and gene therapy services; business consultation services in the nature of technology transfer advice and management in the fields of cell therapy and gene therapy; advertising, marketing and promotional services in the fields of cell therapy and gene therapy; information, advisory and consultancy services related to the aforesaid

Medical services relating to the removal, treatment and processing of stem cells; medical services, namely, stem cell therapy services; medical services, namely, gene therapy services; stem cell bank services, namely, stem cell storage; information, advisory and consultancy services related to the aforesaid

Scientific research, development and testing services in the fields of cell therapy and gene therapy; research and development of new products for others in the fields of cell therapy and gene therapy; pharmaceutical and biopharmaceutical research and development services in the fields of cell therapy and gene therapy; scientific consultancy services in the fields of designing, building, testing and validating processes and systems for use in cell therapy and gene therapy services; design and development of computer hardware and software in the biopharmaceutical, cell therapy and gene therapy fields; development of computer databases in the biopharmaceutical, cell therapy and gene therapy fields; scientific development of custom assays for cell therapy and gene therapy; stem cell research services; information, advisory and consultancy services related to the aforesaid

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 22, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 22, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 2, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 2, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Mar 14, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 13, 2025 AITU
USE AMENDMENT FILED
Jan 9, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 9, 2025 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 9, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 14, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 14, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 5, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 2, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 30, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 30, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 30, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 27, 2023 NWOS
NEW APPLICATION ENTERED
May 2, 2023 NWAP